Core One Labs Enters Into LOI For First Sale Of Its Psychedelic Compounds
Core One Labs Enters Into LOI For First Sale Of Its Psychedelic Compounds
GMP Drug Inc., a wholly-owned subsidiary of Core One Labs Inc. (OTCQB:CLABF) (CSE:COOL)(Frankfurt:LD6) (WKN: A3CSSU) has entered into a non-binding letter of intent with Zollaris Laboratories Corporation, an arms-length party, in pursuit of a potential transaction involving the sale by GMP Drug of psychedelic compounds including but not limited to biosynthetic psilocybin, psilocin, DMT formulated by Vocan Biotechnologies Inc. and Awakened Biosciences Inc., each also wholly-owned subsidiaries of Core One.
GMP Drug Inc.，的全资子公司 Core One Labs Inc (OTCQB: CLABF) (CSE: COOL) (法兰克福:LD6) (WKN: A3CSSU) 有 与 Zollaris 实验室公司签订了一份不具约束力的意向书，一个独立的当事方，正在进行一项涉及 销售 作者：GMP 药物 的迷幻化合物，包括但不限于生物合成的 psilocybin、psilocin、DMT 制定者 沃肯生物技术公司 和 Awakened Biosciences，两家公司也是Core One的全资子公司。
Zollaris is a licensed pharmaceutical company that currently holds a license to possess, and conduct laboratory analysis on, psilocybin. The LOI proposes that GMP Drug will enter an arrangement in which Awakened and Vocan will formulate and GMP Drug will supply proprietary psychedelics produced using the patent-pending production methods of Awakened and Vocan, to Zollaris, pursuant to a definitive agreement, the terms of which are currently under negotiation. It is anticipated that the proprietary psychedelic compounds will be supplied to Zollaris at an agreed upon cost per gram, and in amounts requested by Zollaris.
Zollaris是一家持牌制药公司，目前持有持有psilocybin并对其进行实验室分析的许可证。意向书提议，GMP Drug将达成一项安排，根据最终协议，Awakened和Vocan将配制，GMP Drug将向Zollaris提供使用Awakened和Vocan正在申请专利的生产方法生产的专有迷幻药，协议条款目前正在谈判中。预计专有的迷幻化合物将按商定的每克成本和Zollaris要求的数量提供给Zollaris。
The definitive agreement is anticipated to incorporate the principal terms set forth in the LOI and, in addition, such other terms and provisions of a more detailed nature as the parties may agree upon and as are customary for transactions of this nature. The consummation of the final supply arrangement is subject to a number of conditions, including the satisfaction of each party's respective due diligence, the negotiation and execution of the definitive agreement and Zollaris holding a valid controlled substances license from Health Canada permitting the acquisition and possession of psilocybin.
预计最终协议将纳入意向书中规定的主要条款，此外还包括双方可能商定的以及此类性质交易的惯常性质更详细的其他条款和条款。最终供应安排的完成受许多条件的约束，包括双方各自的尽职调查得到满足、最终协议的谈判和执行，以及Zollaris持有加拿大卫生部颁发的允许购买和拥有psilocybin的有效受控物质许可证。
Photo: Benzinga edit with photos by geralt and sergeitokmakov on Pixabay
照片：Benzinga 在 Pixabay 上用 geralt 和 sergeitokmakov 的照片进行编辑
Benzinga Cannabis Capital Conference
本辛加大麻资本会议
The Benzinga Cannabis Capital Conference, the place where deals get done, is returning to Chicago this Sept 27-28 for its 17th edition. Get your tickets today before prices increase and secure a spot at the epicenter of cannabis investment and branding.
Benzinga Cannabis Capital Conference是达成交易的地方，将于9月27日至28日重返芝加哥参加第17届会议。在价格上涨之前立即获取门票，并在大麻投资和品牌的中心占有一席之地。
Related News
相关新闻
Core One In Talks With Multiple Companies To Supply Psilocybin
Core One 正在与多家公司就供应 psilocybin 进行谈判